Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
Table 1
Patient characteristics.
Characteristic
Suspension patients ()
Tablet Patients ()
value
Age (yr), median (range)
57 (18–84)
56 (20–75)
0.90
Male gender, (%)
59 (50)
37 (58)
0.31
Weight (kg), median (range)
84 (38–175)
89 (59–194)
0.14
(kg/m2), median (range)
30 (15–65)
29.1 (17–59)
0.91
BMI > 30 kg/m2, median (range)
58 (49)
30 (47)
0.77
Diagnosis, (%)
Acute myeloid leukemia
115 (97)
60 (94)
0.21
Myelodysplastic syndrome
3 (3)
4 (6)
Chemotherapy regimen, (%)
Cytarabine-anthracycline (7 + 3)
80 (68)
48 (75)
0.016
High-dose cytarabine-based
15 (13)
0 (0)
Clofarabine-based
7 (6)
5 (8)
Mitoxantrone-etoposide
5 (4)
2 (3)
Other
11 (9)
9 (14)
Mucositis, (%)
23 (19)
7 (11)
0.14
Diarrhea, (%)
24 (20)
12 (19)
0.80
Vomiting, (%)
14 (12)
7 (11)
0.85
Nutritional (%)
Category 1
43 (36)
39 (61)
0.004
Category 2
41 (35)
16 (25)
Category 3
18 (15)
8 (13)
Unknown
16 (14)
1 (2)
Acid suppression therapy, (%)
Proton pump inhibitor
44 (37)
21 (33)
0.18
H2 receptor antagonist
69 (58)
43 (67)
None
5 (4)
0 (0)
, body mass index. status: Category 1: consumption of >75% of meals or >2 nutritional supplements per day; Category 2: consumption of 50%–75% or 1-2 nutritional supplements per day; Category 3: consumption of <50% of meals or no nutritional supplements per day.
